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Abstract
In this paper, we propose a class of multivariate random effects models allowing for the inclusion
of study-level covariates to carry out meta-analyses. As existing algorithms for computing
maximum likelihood estimates often converge poorly or may not converge at all when the random
effects are multi-dimensional, we develop an efficient expectation–maximization algorithm for
fitting multi-dimensional random effects regression models. In addition, we also develop a new
methodology for carrying out variable selection with study-level covariates. We examine the
performance of the proposed methodology via a simulation study. We apply the proposed
methodology to analyze metadata from 26 studies involving statins as a monotherapy and in
combination with ezetimibe. In particular, we compare the low-density lipoprotein cholesterol-
lowering efficacy of monotherapy and combination therapy on two patient populations (naïve and
non-naïve patients to statin monotherapy at baseline), controlling for aggregate covariates. The
proposed methodology is quite general and can be applied in any meta-analysis setting for a wide
range of scientific applications and therefore offers new analytic methods of clinical importance.
Keywords
aggregate covariates; heterogeneity; normal meta-regression models; multiple trials; random
effects; variable selection
1. Introduction
An estimated 12 million Americans are taking cholesterol-lowering drugs, and experts are
recommending that another 23 million should be taking them. The National Cholesterol
Education Program has issued treatment guidelines identifying low-density lipoprotein
cholesterol (LDL-C, ‘bad’ cholesterol) as a causative factor for coronary heart disease and
as the main target for cholesterol-lowering and lipid-lowering therapy. Cholesterol-lowering
medicines called ‘statins’ work mainly in the liver to decrease the production of cholesterol
and reduce cholesterol in the bloodstream. This class of drugs includes: atorvastatin
(Lipitor), simvastatin (Zocor), lovastatin (Mevacor), rosuvastatin (Crestor), pravastatin
(Pravachol), and fluvastatin (Lescol). On the other hand, a drug called ezetimibe (Zetia)
works in the digestive tract. It is unique in the way it helps block absorption of cholesterol
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that comes from food. Ezetimibe (EZE) can complement statins in targeting both sources of
cholesterol.
In general, statins positively affect the lipid profile by increasing high-density lipoprotein
cholesterol (HDL-C, ‘good’ cholesterol) and decreasing LDL-C and triglycerides (TG).
Clinical studies have shown that statins significantly reduce the risk of heart attack and
death in patients with coronary artery disease and can also reduce cardiac events in patients
with high cholesterol levels. Statins are the first-line treatment in most patients, but lipid
goals are frequently not achieved because of inadequate response to therapy, poor
compliance, or concerns regarding the increased potential for side effects at higher doses.
EZE can be given as monotherapy to lower cholesterol levels in patients who are intolerant
to statin or in whom treatment with statin is not appropriate. EZE can also be used in
combination with a statin in patients whose cholesterol levels remain elevated despite
treatment with statin alone. It can be either co-administered with the statin dose or given as a
fixed-dose combination tablet (known as Vytorin) containing EZE and simvastatin.
There has been a rich literature on statistical methods using random effects models for meta-
analysis for the past 20 years. Now, random effects modeling for meta-analysis has become
well accepted (e.g., [1–12]). A number of meta-analyses investigating efficacy and safety of
various statins have been reported in the literature over the last 5 years. See, for example,
[13, 14], the Cholesterol Treatment Trialists Collaboration Group [15], and [16]. There have
been also meta-analyses reported in the literature comparing safety and efficacy of
monotherapy with statins versus combination therapy of EZE added to statins
(coadministration or combination tablet). Mikhailidis et al. [17] performed a meta-analysis
to investigate the cholesterol-lowering effect of EZE added to ongoing statin therapy.
Another meta-analysis involving 14 clinical trials was done by Catapano et al. [18] to
investigate the lipid-altering efficacy of EZE co-administered with simvastatin compared
with Rosuvastatin.
Common features of the meta-analyses cited previously are a lack of incorporation of (or
adjusting for) any covariates through modeling and the lack of accommodating and
assessing several types of treatments across studies. Also, most of the meta-analyses
conducted in the literature are for adverse event comparisons, and such analyses use
outcome measures of either odds ratios or relative risks. An outcome measure of mean
difference is frequently used for efficacy comparisons, which is our primary analysis and
outcome measure in this paper. While carrying out a meta-analysis, it is crucial to account
for and understand differences among the studies to be combined with respect to study
design, duration of treatment, durations of follow-up, and patient population, which is a
function of entry criteria. As can be seen from Tables I–III, the treatment arms, treatment
durations, and patient entry criteria for the studies considered here varied considerably,
warranting inclusion of covariates into the model. The study-level aggregate estimates
available from individual publications (listed in Tables I and II) and used in the meta-
analysis here were indeed adjusted for selected covariates, but the set of selected covariates
varied from study to study. Thus, the available aggregate estimates were not uniformly
adjusted and again warrant the inclusion of important covariates in the meta-analysis.
There are some recent developments on meta-regression models. See, for example, [19–26].
Compared with the current literature on meta-regression, our contributions in this paper are
several-fold. First, we develop novel meta-analysis models on the basis of multi-dimensional
random effects that allow for study-level covariates and general covariance matrices for the
random effects. Next, we develop an efficient expectation–maximization (EM) algorithm for
fitting these models and develop methods for examining heterogeneity and variable selection
for these models. Specifically, for assessing heterogeneity, we generalize Cochran’s Q
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statistic [27] to meta-analysis regression models with covariates and multi-dimensional
random effects in order to test homogeneity among studies. Finally, we have assembled a
dataset on the basis of 26 large clinical studies and have applied the proposed methods to
this dataset in order to address some important clinical questions. We organize the rest of
this paper as follows. In Section 2, we give a detailed description of the LDL-C data on the
basis of the 26 studies and discuss the specific hypotheses of interest for these studies. In
Section 3, we give the full development of the meta-analysis regression models with multi-
dimensional random effects in Section 3.1, present an extension of Cochran’s Q in Section
3.2, and provide the necessary mathematical formulation of three variable selection criteria
in Section 3.3, respectively. In Section 4, we carry out an extensive simulation study to
examine the performance of the proposed methods. Section 5 presents a detailed analysis of
the LDL-C data, and we conclude the paper with some discussion and extensions of the
proposed methodology in Section 6. The detailed development of the EM algorithm
including closed-form expressions for the E-step and the estimates in the M-step is given in
the Appendix.
2. Low-density lipoprotein cholesterol data
In this paper, we carry out aggregate data meta-analyses to evaluate the LDL-C lowering
effect of EZE in combination with statin in comparison with statin alone in randomized
controlled trials on treatment-naïve patients at baseline (on a first-line therapy) and those
continuing on statins at baseline (on a second-line therapy). The objective is to evaluate the
LDL-C lowering effect of EZE added to statin versus statin in treatment-naïve patients or
EZE added to baseline statin versus placebo added to baseline statin in statin-treated
patients. The study inclusion criteria were Merck-sponsored double-blind, randomized,
active or placebo-controlled clinical trials on adult patients with primary
hypercholesterolemia.
These criteria led to 26 studies whose titles, treatment groups, treatment durations, number
of patients, and the citations of primary publications are given in Table I for the first-line
therapy studies and Table II for the second-line therapy studies. These trials were conducted
between November 1999 and October 2008, and study durations ranged from 4 to 24 weeks.
Some trials had longer durations with titration of doses, but only the data prior to the first
titration were used in the analyses. The primary end point in these trials was the percent
reduction in LDL-C from baseline. The entry criteria for the patients in each of these studies
are summarized in Table III. Figure 1 shows the forest plots of the metadata for these 26
studies. Note that the reported means were model-based means. In practice, the patient-level
data are not available to the researchers, and hence our focus here is on aggregate data meta-
analysis instead of patient-level data meta-analysis.
For the analyses, different statins and their doses are combined to form the statin and (statin
+ EZE) treatment groups. EZE is available at only one dose of 10 mg, and the statins used in
these studies included simvastatin, atorvastatin, lovastatin, rosuvastatin, pravastatin, and
fluvastatin. The following hypotheses are of interest: H01: No treatment differences
(addition of EZE has no effect) with respect to LDL-C lowering (percent reduction) in the
first-line therapy studies; H02: No treatment differences (addition of EZE has no effect) with
respect to LDL-C lowering (percent reduction) in the second-line therapy studies; and H03:
Treatment differences within the first-line and second-line therapy studies are the same.
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3. Methods for meta-analysis with multi-dimensional random effects and
aggregate covariates
3.1. The meta-analysis regression model
Consider K randomized trials (studies), where each trial has J treatment arms, and patients in
each trial are either all on the first-line therapy or the second-line therapy prior to the trial.
Let yjk denote the aggregate response with a known precision parameter wjk. Let Ik be the
indicator function such that Ik = 1 if patients are on the second-line therapy and Ik = 0 if
patients are on the first-line therapy. Also let xjk denote a p-dimensional vector of aggregate
covariates for j = 1, 2, …, J and k = 1, 2, …, K. Then, we propose the following normal
random effects model for the meta-analysis:
(3.1)
where β = (β1, β2, …, βp)′ is the vector of fixed effects regression coefficients corresponding
to the p aggregate covariates and
(3.2)
independently, for j = 1, 2, …, J and k = 1, 2, …, K. Let γR,1k = (γ1k1, γ1k2, …, γ1kJ)′, and
γR,2k = (γ2k1, γ2k2, …, γ2kJ)′, which represent the vectors of random effects of the first-line
and second-line therapies for the model. Thus,  represents the vector of
random effects for the model. We assume γR,1k and γR,2k are independent, and
(3.3)
where Vℓ = (Vℓjj′) is an unknown J × J covariance matrix and γℓ = (γℓ1, …, γℓJ)′ denotes the
vector of the overall treatment effects when patients were on the ℓth line therapy for ℓ = 1, 2.
Let  and . Using (3.3), we have γR,k = γ + ξk and ξk ~ N2J(0, V),
where V = diag(V1, V2).
We have proposed here a very general class of meta-regression models that are suited for
analyzing metadata from studies involving first-line and second-line therapies. Such studies
are becoming quite prominent in diabetes, cardiovascular, and cancer clinical trials where
patients received a prior therapy that is identical or nearly identical to the therapy for the
current clinical trial. Such types of studies pose many new challenges in the meta-regression
setting such as multivariate and correlated random effects that lead to potentially high
dimensional variance components. The meta-analysis regression model defined by (3.1),
(3.2), and (3.3) is very general, which can accommodate several treatments in first-line and
second-line as well as a large number of covariates. However, the resulting model requires
estimation of the covariance matrix of the random effects, denoted by V, which is a block
diagonal matrix. Simultaneous estimation of (V, γ, β) is not trivial and requires a
sophisticated and computationally intensive EM algorithm, which is developed in the
Appendix.
3.2. Test of statistical homogeneity
The hypotheses for heterogeneity across K studies are H0: V = 0 versus H1: V > 0, where V
> 0 denotes that V is a positive definite matrix. In this regard, we extend the Q test statistic
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for homogeneity proposed by Cochran [27] to meta-analysis regression models with
multivariate random effects. In (3.3), when V = 0, γR,1 = ··· = γR,K = γ, indicating that there
is no heterogeneity across the K studies. As γR,k in (3.3) is a q-dimensional vector of random
effects, the classical Q function of Cochran [27] is not well defined. In this case, we propose
the following extension of the Q test statistic:
(3.4)
where , yk = (y1k, …, yJk)′, Wk = diag(w1k, …,
wJk),  is a J×(p+2J) matrix, Xk = (x1k, …, xJk)′ is a J × p matrix, Zk = (z1k, …,
zJk)′ is the J × 2J matrix, and , where ej = (0, …, 1, …, 0)′ with a 1 in
its jth component and 0 elsewhere, for j = 1, …, J. Similar to [27], we can show that under
the hypothesis of homogeneity, V = 0, and assuming that the regression model is correct,
. Thus, if the regression model is correct, a rejection of the null hypothesis
implies that there is heterogeneity across the K studies. However, without knowledge of
whether the regression model is correct, a rejection of the null hypothesis implies either
heterogeneity or misspecification of the regression model.
3.3. Variable selection for meta-analysis regression models
Let η = (ϕ, V−1), where ϕ = (β′, γ′)′, denotes the collection of all the unknown parameters.
Write  for j = 1, …, J and Xk = (x̃1k, x̃2k)′. For the meta-regression model
defined by (3.1), (3.2), and (3.3), the marginal distribution of yk is analytically available.
After some algebra, we obtain
Thus, the observed-data log-likelihood is given by
We consider three variable selection criteria for selection of the covariates in our meta-
regression model, namely, the Akaike information criterion (AIC), Bayesian information
criterion (BIC), and a finite-sample corrected version of AIC (AICC). These criteria are
computed as follows:
where η̂ is the MLE of η and q = p + 2J + J(J + 1) is the dimension of η. See [28] and [29]
for additional details. We mention here that in our variable selection procedure, γ and V are
always kept in every model and, therefore, are never candidates for selection. Our variable
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selection procedure is only concerned with selecting the covariates xjk, that is, components
of β.
4. A simulation study
To examine the performance of the proposed method, we carry out a simulation study with
K = 26 trials and four trial-level covariates. Among the 26 trials, 13 are the first-line therapy
trials, and the remaining 13 are the second-line trials. Within each trial, two treatment arms
(J = 2) are assumed. The sample sizes, njk, were chosen to be the same as those in the LDL-
C data discussed in Section 2. The within-subject standard deviations were set to the values
of the standard errors (SEs), SDjk, estimated from the LDL-C data. We used the values of
baseline LDL-C, baseline HDL-C, age in years, and duration in weeks from the LDL-C data
for these four covariates. Then, we generated the simulated data from the nine meta-
regression models defined by (3.1), (3.2), and (3.3) with various combinations of β and V.
Specifically, γ11 = −52, γ12 − γ11 = −12, γ21 = −23, and γ22 − γ21 = −20 were used in all the
nine meta-regression models. To evaluate the performance of the model selection criteria,
we considered three covariate models (C-Models), namely, C-Model I: β = (0.1, −0.7, 0.6,
1.0) (four covariates); C-Model II: β = (0.1, −0.7, 0.0, 1.0) (three covariates); and C-Model
III: β = (0.1, 0.0, 0.0, 1.0) (two covariates), respectively. For each covariate model, we
considered three different values of V (the covariance matrix of the random effects) such
that V = V0 (large between-study variability), V = V0/2 (moderate between-study
variability), and V = V0/10 (small between-study variability), where V0 = diag(V01, V02),
 and . For each meta-regression model, we
generated 1000 simulated data sets, and for each simulated dataset, we fit 16 models. AIC,
AICC, and BIC were computed for all 16 models, whereas the estimates of the model
parameters were computed, and the test of statistical homogeneity was performed only under
the true model, which was used to generate the simulated data.
Let ϕj denote the jth component of ϕ. Also, let ϕ ̂ij and SE(ϕ ̂ij) be the maximum likelihood
estimate of ϕj and the SE of ϕ ̂ij from the ith simulated dataset for i = 1, 2, …, 1000. We
define the simulation estimate (EST) and the SE to be  and .
We also define the root of the mean squared error (RMSE) as ,
where  is the true value of ϕj. Table IV shows ESTs, SEs, RMSEs, and powers of β and γ
under the nine combinations of β and V, where the power was calculated on the basis of a
significance level of 0.05. From Table IV, we see that for all parameters, the ESTs were
very close to the corresponding true values, and the SE and RMSE become smaller and the
power increases when the number of covariates is less or there is less between-study
variability. In particular, under C-Model III, the parameter estimates were quite accurate and
had good powers given that the number of trials (K = 26) is relatively small. We notice that
under C-Models I and II, when V is large, the estimate of γ21 has much lower power than
that of γ11, which is expected as the effect size of γ21 is much smaller than the one of γ11. In
addition, we computed the coverage probability (CP) of the 95% confidence interval on the
basis of a normal approximation. The respective CPs for ( ) in
the 1000 simulations when V = V0, V0/2, and V0/10 were (92.3%, 93.4%), (91.6%, 93.5%),
and (92.4%, 95.0%) under C-Model I; (92.9%, 93.2%), (91.7%, 93.8%), and (92.4%,
94.7%) under C-Model II; and (93.0%, 93.5%), (91.6%, 93.8%), and (92.1%, 94.8%) under
C-Model III. The CPs for the other parameters were similar and thus not reported here for
brevity.
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Table V presents the frequencies of ranking the true model as one of the top three models
under each of the AIC, AICC, and BIC criteria. From Table V, we see that AIC outperforms
both AICC and BIC when the full model is the correct model and the between-study
variability is large. The results in this table also indicate that the performance of all three
criteria improves when the between-study variability becomes smaller, and all three criteria
perform well when the between-study variability is small. Under C-Model II, the
percentages of ranking the true model as one of the top three models in the 1000 simulations
were 85.2%, 93.9%, and 99.8% for AIC, 78.1%, 93.3%, and 99.8% for AICC, and 77.5%,
93.5%, and 99.8% for BIC when V = V0, V0/2, and V0/10, respectively. In this sense, AIC
performs slightly better than AICC and BIC. When C-Model III is the correct model, both
AICC and BIC perform better than AIC. When the full model is the correct model, BIC
performs slightly better than AICC, whereas AICC does slightly better than BIC when C-
Models II and III are the correct models. Overall, AIC tends to select a larger model,
whereas both AICC and BIC are in favor of smaller models.
In all nine simulation settings, we carried out the test of statistical homogeneity via the Q
test statistic given by (3.4). The average values of QK were 1476.2, 761.0, and 188.3 for V =
V0, V0/2, and V0/10 under C-Model I; 1633.1, 840.0, and 204.9 for V = V0, V0/2, and V0/10
under C-Model II; and 1778.2, 913.0, and 220.3 for V = V0, V0/2, and V0/10 under C-Model
III. In all nine simulations, the Q statistic rejected the hypothesis of homogeneity; that is, V
= 0, 100% of the time in the 1000 simulated data sets, resulting in 100% power. We note
that  and , and, hence, the variances
are relatively small compared with the effect sizes of the treatments. We also conducted a
simulation study with V = 0. That is, we generated the data from (3.1) and (3.2) with γ1jk =
γ1j and γ2jk = γ2j for j = 1, 2. Under C-Model I, the average value of QK was 44.7, and the Q
test rejected the hypothesis that V = 0, 54 times in the 1000 simulations at a significance
level of 0.05. Note that under this simulation setting, , the 95th percentile of
 is 60.5, and hence, the average value of QK is much smaller than this chi-square
percentile. This result implies that the type I error of the Q test was about 5%. For the 1000
data sets generated under C-Model I, we also fit all 15 reduced models with zero to three
covariates and then performed the Q test for each of these models. In this case, all 15
regression models were misspecified. The average values of Qk ranged from 198.3 to 635.2,
the minimum values of Qk ranged from 120.1 to 492.7, and all p-values were less than
0.00001 for these 15 models. Similar results were obtained under C-Models II and III. These
results further demonstrate that the Q statistic can be used to test either heterogeneity or
misspecification of the regression model as discussed in Section 3.2.
5. Analysis of low-density lipoprotein cholesterol data
For the LDL-C data, yjk denotes the percent reduction of LDL-C and , where
SDjk and njk denote the standard deviation of the mean LDL-C and the sample size,
respectively, for the jth treatment in the kth trial. There were K = 26 studies, the first-line
and second-line therapies were ‘not on statin’ and ‘on statin’ prior to the trial, and there were
two treatment arms (J = 2) corresponding to ‘statin alone’ and ‘statin + EZE’. We
considered eight aggregate covariates, including baseline LDL-C, baseline HDL-C, and
baseline TG, age in years, white (%), male (%), diabetes mellitus (DM) (%), and duration in
weeks. Thus, we have xjk = ((baseline LDL-C)jk, (baseline HDL-C)jk, (baseline TG)jk, agejk,
whitejk, malejk, DMjk, Durationjk )′ and the vector of corresponding regression coefficients
is β = (β1, …, β8)′ with p = 8 under the full model. We carried out variable selection for the
meta-analysis regression model given in (3.1). We computed AICs, AICCs, and BICs for all
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28 = 256 possible models. Table VI shows the values of these measures for the top three
AIC models along with the no covariate model. The top three AIC models were (baseline
LDL-C, baseline HDL-C, Duration), (baseline LDL-C, Duration), and (baseline LDL-C,
baseline HDL-C, age, Duration), and the corresponding AIC values were 315.7, 316.6, and
316.6. The top AIC model, (baseline LDL-C, baseline HDL-C, Duration), is the third best
BIC model with BIC=332.1 and the sixth best AICC model with AICC = 325.3. The second
best AIC model, (baseline LDL-C, Duration), is also the second best AICC and BIC model.
The no covariate model and the full model had AIC values of 318.8 and 323.8, which were
ranked 23 and 196, respectively. The no covariate model is the best AICC model as well as
the best BIC model. The third best AICC model was the model with a single covariate,
namely, Duration, which was the 13th best AIC model and the fourth best BIC model. The
values of AICC, AIC, and BIC for the model (Duration) were 325.0, 318.5, and 332.3. As
shown in the simulation study, AIC tends to select a larger model, whereas AICC and BIC
are in favor of a smaller model as both AICC and BIC penalize the dimension of the model
parameters more than AIC. In practice, AIC is more conservative and desirable compared
with AICC and BIC in variable selection as it penalizes the dimension of the model
parameters less and avoids the misidentification of potentially important covariates. Table
VI also shows the values of QK. Thus, the QK test rejects the hypothesis of no heterogeneity,
which implies that there was heterogeneity across the K = 26 studies. This was confirmed by
the large values of the maximum likelihood estimates of the Vjj’s as shown in Table VII. In
addition, we fit the meta-regression models with no random effects (V = 0), a single random
effect for each of the first-line therapy trials (V122 = 0), a single random effect for each of
the second-line therapy trials (V222 = 0), and a single random effect for all trials (V122 =
V222 = 0). Under the best AIC model, the AIC values were 1632.9, 533.4, 395.3, and 643.5
corresponding to these four types of random effects models. These AIC values were much
larger than 315.7 under the model with four random effects. Similar results were obtained
under other covariate models. These results further confirmed that there was heterogeneity
of treatment effects within first-line and within second-line trials.
Table VII shows the parameter estimates under the best AIC model. From this table, we see
that baseline LDL-C and duration were significant with p-values of 0.0277 and 0.0181,
respectively. The positive coefficient for baseline LDL-C in the model implies that the
higher the baseline LDL-C value was, the lower the percent reduction in LDL-C. Similarly,
the longer the study duration, the lower the percent reduction in LDL-C. This might be due
to a full realization of the beneficial effect of statins over the first several weeks, which
might be difficult to fully sustain over the long run because of a possible lack of drug
compliance. The predicted percent changes from baseline in LDL-C for patients on statin
and EZE/statin in first-line therapy studies were −38.50 and −50.47, respectively. The
predicted percent changes from baseline in LDL-C for patients on statin and EZE/statin in
second-line therapy studies were −7.55 and −27.53, respectively. The treatment differences
for first-line and second-line therapy studies were −11.97 and −19.97, respectively, which
were statistically significant each with p-value <0.0001. The treatment difference for
second-line therapy studies was significantly higher than that for first-line therapy studies.
We also fitted two other models (no covariate model and a full model with all eight
covariates) for sensitivity analysis. The results of these two models were consistent with the
best AIC model as seen from Table VII.
Under the meta-analysis regression model specified by (3.1), (3.2), and (3.3), the three
hypotheses stated in Section 2 can be mathematically written as H01: γ12 = γ11; H02: γ22 =
γ21; and H03: γ22 − γ21 = γ12 − γ11. These three hypotheses were all rejected under the best
AIC model as shown in Table VII. Rejection of these hypotheses implies that there were
treatment differences within first-line and second-line studies, and there were unequal
treatment differences between first-line and second-line studies. Rejection of these
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hypotheses also indicates that EZE had a significant effect within first-line and second-line
studies and that LDL-C lowering due to statin was different between first-line and second-
line studies. It is worthwhile to note that the aggregate study-level estimates used in our
meta-analysis were already adjusted for baseline LDL-C (along with other covariates which
varied from study to study), and yet baseline LDL-C still remained a significant covariate in
both the final AIC model and the full model. This indicates differences among study
populations and study characteristics and again emphasizes the importance of incorporating
study-level covariates into the meta-analysis model. It should also be noted that the no
covariate model is nested in the best AIC model, whereas the best AIC model is nested in
the full model. The nested nature of these three models allows us to make a formal statistical
comparison of the three models via likelihood ratio tests. On the basis of the likelihood ratio
tests, we found that the best AIC model provided a significantly better fit than the no
covariate model (p-value = 0.0288); however, the full model did not provide a significantly
better fit than the no covariate model because of possible over-fitting of the data (p-value =
0.2024); and, in addition, the best AIC model fit the data equally well as the full model (p-
value = 0.8564). Interestingly, the maximum likelihood estimates of the treatment effects
were similar in all three models.
The EM algorithm discussed in the Appendix was implemented using FORTRAN 95 with
IMSL. The convergence criterion for the EM algorithm for obtaining the MLEs was that the
squared distance of all the model parameters between the tth and (t + 10)th iterations was
less than 10−7. This algorithm converged in approximately 1000 iterations for all models we
considered in both the simulation study and the analysis of the LDL-C data. The FORTRAN
95 code is available upon request.
6. Discussion
Our goal in this investigation was to develop a novel class of models for meta-analysis
incorporating study-level covariates and be able to fit these models in order to study the
impact of study-level covariates on the response variable. We applied this technique to an
important problem in the field of cholesterol reduction and studied the effect of adding EZE
to a class of drugs called statins through aggregate meta-analysis controlling for some of the
important study-level covariates. Our proposed variable selection procedure led us to our
best AIC model with three covariates: baseline LDL-C, baseline HDL-C, and study duration.
This model provided a significantly better fit over the model with no covariates. The model
implied that the higher the baseline LDL-C is, the lower the percent reduction in LDL-C at
study end. Also, the longer the study duration is, the lower the LDL-C percent reduction.
The latter result is somewhat of a conjecture because the duration of the studies considered
here (as well as for many other randomized clinical trials on statins) did not vary over a
large range. The issue of the impact of study duration remains an open question needing
further investigation. It is worthwhile to reiterate the importance of incorporating covariates
in the meta-analysis model even though the aggregate study-level estimates used in the
meta-analysis may have already adjusted for those covariates. Differences among study
populations and study characteristics necessitates the inclusion of these covariates into the
analysis.
The beneficial effects of statin therapy is well studied and well established. We studied the
effect of combination therapy of EZE along with statins, and our meta-analysis has allowed
us to clearly demonstrate enhanced reduction in LDL-C because of addition of EZE over
and above that due to statins alone. This incremental reduction is clinically as well as
statistically significant. Presently, Vytorin is the only drug approved in the USA by the
FDA, which combines simvastatin and EZE into one tablet. Our analysis has also
established larger between-treatment differences for second-line therapy compared with
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first-line therapy. This implies a larger benefit for combination therapy over statins alone for
patients already on statins (second-line therapy patients).
In summary, our analysis results with this rich dataset reveal the following: (i) statin therapy
is effective, but statins in combination with EZE are even more effective in reducing LDL-
C; (ii) the treatment difference (for % change from baseline) was higher in the second-line
studies and can be attributed, in part, to lower baseline LDL-C values; (iii) baseline LDL-C,
baseline HDL-C, and study duration are important covariates in LDL-C reduction; (iv) while
conducting an aggregate meta-analysis, it is critical to incorporate study-level covariates,
which is not a common practice, and the number of covariates that can be included in the
model is dependent upon the number of studies included in the meta-analysis; and (v) even
though the study-level estimates used in the meta-analysis may be adjusted locally (within
study) for some of the covariates, it is still critical to incorporate these covariates in the
meta-analysis model; in other words, adjusting for covariates at the study level is not
sufficient.
As the model fitting is now done at the study level, one must be careful not to fit too large of
a meta-regression model relative to the number of studies, and the results should be
interpreted with caution. In our case study, we had 26 studies, and each study had two
treatment arms, which yielded 52 data points. The largest model we fit contained 18
parameters, and so we had 34 degrees of freedom left over. In the meta-analysis literature,
there are no current guidelines discussing how large of a model to fit relative to the number
of studies. One needs to use common sense and practical judgment and fit models that yield
stable estimates and SEs, especially for the variance components. In our case study, the
estimates from the largest model were quite stable, and the EM algorithm always converged
in relatively few iterations, thus giving us confidence that the models we fit were reasonable.
On the basis of our experience with these data, we would recommend a general rule of
thumb for model fitting that n ≥ 2q, where n denotes the number of data points and q denotes
the total number of parameters in the meta-regression model. In carrying out a variable
selection procedure, there may be an inherent multiplicity issue in the covariate selection
procedure, and as a result one must bear this in mind when carrying out such a procedure
and perhaps conduct simulation studies to examine whether the type I error is controlled
with a given procedure. At the very least, this issue must be acknowledged by the data
analyst.
In Section 3.1, we assume that wjk is a known precision. Because we have only a single
observation for the jth treatment within the kth trial, wjk is not estimable. We need
additional information to estimate wjk. Suppose that the standard deviation, SDjk, is
available. Then, the method recently proposed by Yao et al. [30] can be used to relax the




where  is an unknown variance. As shown in [30], using the profile likelihood approach,
the model using (3.1), (3.2a), and (3.2b) reduces to the model (3.1) when εjk follows a scaled
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Student-t distribution with njk − 1 degrees of freedom and scale parameter  after
profiling out . When njk is large, the Student-t distribution is approximately normal.
Thus, the model using (3.1) and (3.2) with a fixed variance  is approximately the
same as the model defined by (3.1), (3.2a), and (3.2b) when njk is relatively large. For the
LDL-C data, the smallest sample size was 92. Thus, we do not need to estimate wjk, and
instead, we can simply set .
We mention here that the proposed methodology is quite general and can be applied in any
meta-analysis setting including a wide range of scientific applications. We have focused
here specifically on cholesterol-lowering drugs because of our collaborations in this area and
the availability of several datasets. Future work includes extending the proposed
methodology to multivariate responses in meta-analysis models, such as joint modeling of
the percent reduction of LDL-C from baseline, the percent change of HDL-C from baseline,
and the percent reduction of TG from baseline, on the basis of individual patient data or
study-level data. Covariate data are commonly missing at the study level in meta-analysis,
such as body mass index. The literature for analyzing such missing data is quite sparse.
Currently, these clinically important extensions are under investigation.
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Appendix: The complete-data likelihood function and expectation–
maximization algorithm for meta-regression models
The complete-data likelihood function
Let  be the vector of unknown latent variables as defined in (3.3). Then,
the conditional distribution of yk given ϕ and ξk is of the form
where Xk = (x̃1k, x̃2k)′, and conditional on V, ξk has the density
. Ignoring the constants that are free of η and exp ξk, the
complete-data log-likelihood is given by
(A.
1)
Expectation–maximization algorithm for meta-regression models
We develop an efficient EM algorithm to compute the maximum likelihood estimates of η
via the EM by the method of Weights, which was initially introduced by Ibrahim [31] and
further developed by Ibrahim, Chen, and Lipsitz [32] in the context of generalized linear
models with non-ignorable missing covariate data. The algorithm involves two steps: the E-
step and the M-step. Let η(t) = (ϕ(t), (V−1)(t)) denote the value of η at the tth EM iteration.
Note that at the initial EM iteration, V(0) must be chosen to be a block diagonal matrix with
a structure similar to V. To compute the E-step, we must compute the expectation of the
complete-data log-likelihood (A.1) with respect to the conditional distribution of the latent
variables ξk given the observed data. We can write the E-step for the observations from the
kth trial at the (t + 1)st EM iteration as
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where f(ξk|yk, η(t)) is the conditional distribution of ξk given the observed data yk and the
value of η at the tth EM iteration. After much tedious algebra, it can be shown that ξk|yk,
, where  and
. After some algebra, Qk(η|η(t)) reduces to
Thus, the E-step for all the observations from the K trials is given by
.
The M-step maximizes Q(η|η(t)), and closed forms for the parameter estimates are available.
Specifically, the M-step is obtained as follows. First, we find V(t+1) to maximize
which gives
Second, we find ϕ(t+1) to minimize ,
which yields
Let η̂ denote the estimate of η at EM convergence. To obtain the asymptotic covariance
matrix of η̂, we use the method of Louis [33]. Following a similar derivation as in [34], the
estimated observed information matrix of η̂ is given by
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where η̂ is the estimate of η at convergence,
Q̇ denotes the first derivative vector of Q with respect to η, and Q̈ denotes the second
derivative matrix of Q with respect to η. The expectation in (A.2) is taken with respect to the
density f(ξk|yk, η̂).
The estimate of the asymptotic covariance matrix of ϕ ̂ is the upper p* × p* block of [ 
(η̂)]−1, where p* = p + 2J is the dimension of ϕ. Straightforward derivations yield
(A.
3)
Write V* = V−1, , where  for ℓ = 1, 2. Let
which is formed by stacking the columns of the lower triangular portion of  and
which is formed by stacking the columns of . Then, we have
for ℓ = 1, 2. Notice that Σk(t) is a block diagonal matrix. Then, we can write
(A.4)
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where , and  is a J-dimensional vector, and
 is a J × J symmetric matrix for ℓ = 1, 2. Using the matrix derivative formula given in
[35], we obtain
(A.5)
where DJ is the J2 × J(J + 1)/2 duplicated matrix such that . When J = 2,
Again, using the matrix derivative formula given in [35], we have
(A.6)
where ⊗ denotes the Kronecker product, for ℓ = 1, 2. Furthermore, we have .
Using (A.3), (A.5), and (A.6) with both η(t) and η replaced by η̂, we can easily obtain
closed-form expressions of Q̈(η̂|η̂) and Q ̇k(η̂|η̂).
Using the complete-data log-likelihood ℓ(η, ξ), we have
where ξℓk = (ξℓ1k, …, ξℓJk)′ for ℓ = 1, 2. Similar to (A.3) and (A.5), we obtain
and
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for ℓ = 1, 2. Write Zk = (Z1k, Z2k), where Z1k = ((1 − Ik)e1, …, (1 − Ik)eJ)′ and Z2k = (Ike1,






for ℓ = 1, 2. Now, we let KJJ denote a J2 × J2 commutation matrix such that vec(A) = KJJ
vec(A′), where A is a J × J matrix. Also let , where IJ2 is the J2 × J2
identity matrix. Note that
for ℓ = 1, 2. Using Theorem 9.20 of [35] and after some algebra, we obtain
(A.
9)
for ℓ = 1, 2. Finally, we obtain
(A.
10)
We therefore obtain a closed-form expression of E[Sk (η̂; yk, ξk) Sk (η̂; yk, ξk)′|yk, η̂] in (A.
2) via (A.7)–(A.10) with η(t) and η replaced by η̂.
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Forest plots of LDL-C data, where each line corresponds to percent reduction in LDL-C
from baseline with a 95% confidence interval.
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Table VI
The values of AIC, AICC, BIC, and QK for the LDL-C data.
Model AIC AICC BIC QK
Baseline LDL-C, baseline HDL-C, duration 315.7 325.3 332.1 1545.8
Baseline LDL-C, duration 316.6 324.6 331.7 2194.1
Baseline LDL-C, baseline HDL-C, age, duration 316.6 328.0 334.3 1362.1
No covariates 318.8 324.1 331.3 3033.6
Note that the p-values associated with QK statistics were all < 0.0001.
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